Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to levodopa in pat
Invitation to presentation of BioArctic s Full Year Report for the period January - December 2020 on February 4 at 9.30 a.m. CET
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)
will publish the company s Full Year Report for the period January - December 2020 on
Thursday, February 4, 2021, at 08:00 a.m. CET.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on February 4, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Full Year Report for the period January - December 2020, followed by a Q&A-session.
To attend, please dial-in at one of the numbers below, from:
BioArctic receives European patent for new antibodies targeting Alzheimer s disease
STOCKHOLM, Jan. 27, 2021 /PRNewswire/
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.
BioArctic s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer s disease.
/PRNewswire/ BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company s Full Year Report for the period January - December 2020 on Thursday,.